Pass; Martin

Patent Applications and Registrations

Patent applications and USPTO patent grants for Pass; Martin.The latest application filed is for "pyrimidine derivatives".

Company Profile

0.4.16

Pass; Martin - Macclesfield GB
Pass; Martin - Hertfordshire GB
Pass; Martin - Cheshire GB
Pass; Martin - Maclesfield GB
Pass; Martin - Stevenage GB
Pass; Martin - StockPort GB

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer Grant 7,893,063 - Pass February 22, 2	2011-02-22
Pyrimidine Derivatives App 20100267755 - Bravi; Gianpaolo ; et al.	2010-10-21
2-benzimidazolyl-6-morpholino-4- (azetidine, Pyrrolidine, Piperidine Or Azepine) Pyrimidine Derivatives As Pi3k And Mtor Inhibitors For The Treatment Of Proliferative Disorders App 20100022534 - Butterworth; Sam ; et al.	2010-01-28
2-benzimidazolyl-6-morpholino-4-phenylpyrimidine Derivatives As Pi3k And Mtor Inhibitors For The Treatment Of Proliferative Disorders App 20090325954 - Butterworth; Sam ; et al.	2009-12-31
2-heterocycloamino-4-imidazolylpyrimidines As Agents For The Inhibition Of Cell Proliferation App 20090275567 - Jones; Clifford ; et al.	2009-11-05
Pyrimidine Derivatives App 20090270390 - Butterworth; Sam ; et al.	2009-10-29
2-benzimidazolyl-6-morpholino-4-piperidin-4-ylpyrimidine Derivatives As Pi3k And Mtor Inhibitors For The Treatment Of Proliferative Disorders App 20090233926 - Butterworth; Sam ; et al.	2009-09-17
2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer App 20090143384 - Pass; Martin	2009-06-04
2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer App 20080058332 - Bailey; John Peter ; et al.	2008-03-06
2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer App 20080051401 - Pass; Martin	2008-02-28
Novel fused triazolones and the uses thereof App 20070149560 - Ashwell; Susan ; et al.	2007-06-28
Quinazoline derivatives as antitumor agents App 20070088044 - Hennequin; Laurent Francois Andre ; et al.	2007-04-19
Quinazoline derivatives as antitumor agents App 20070082921 - Hennequin; Laurent Francois Andre ; et al.	2007-04-12
Substituted pyrimidines as selective cyclooxygenase-2 inhibitors Grant 7,084,148 - Carter , et al. August 1, 2	2006-08-01
Substituted pyrimidines as selective cyclooxygenase-2 inhibitors App 20050282845 - Carter, Malcolm Clive ; et al.	2005-12-22
Quinazoline derivatives as antitumor agents App 20050054662 - Hennequin, Laurent Francois Andre ; et al.	2005-03-10
Substituted pyrimidines as selective cyclooxygenase-2 inhibitors App 20040102466 - Carter, Malcolm ; et al.	2004-05-27
Adenosine derivatives and methods of administration Grant 6,677,316 - Bays , et al. January 13, 2	2004-01-13
Benzamide derivatives as thrombin inhibitors Grant 6,670,381 - Kelly , et al. December 30, 2	2003-12-30
Adenosine derivatives App 20030096788 - Bays, David Edmund ; et al.	2003-05-22

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.